Category C—No reports describing the use of ramelteon in human pregnancy have been located. Although the animal data are reassuring, the absence of human pregnancy experience prevents a better assessment of the embryo-fetal risk.
No reports describing the use of ramelteon during human lactation have been located. The molecular weight (about 259), serum protein binding (about 82%), and the elimination half-life suggest that the drug will be excreted into breast milk. The effect of this exposure on a nursing infant is unknown.
No dosage adjustment necessary
No dosage adjustment necessary
With 4 active metabolites, even mild impairment can ↑ levels 4-fold
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated August 08 2019 14:18:39. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.